- Home
- ALBT vs KPRX Comparison
ALBT vs KPRX Comparison
Compare ALBT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALBT
- KPRX
- Stock Information
- Founded
- ALBT 2014
- KPRX 1998
- Country
- ALBT United States
- KPRX United States
- Employees
- ALBT N/A
- KPRX N/A
- Industry
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALBT Health Care
- KPRX Health Care
- Exchange
- ALBT Nasdaq
- KPRX Nasdaq
- Market Cap
- ALBT 7.4M
- KPRX 8.7M
- IPO Year
- ALBT N/A
- KPRX N/A
- Fundamental
- Price
- ALBT $2.28
- KPRX $2.93
- Analyst Decision
- ALBT
- KPRX Strong Buy
- Analyst Count
- ALBT 0
- KPRX 1
- Target Price
- ALBT N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ALBT 1.4M
- KPRX 93.7K
- Earning Date
- ALBT 08-26-2025
- KPRX 08-08-2025
- Dividend Yield
- ALBT N/A
- KPRX N/A
- EPS Growth
- ALBT N/A
- KPRX N/A
- EPS
- ALBT N/A
- KPRX N/A
- Revenue
- ALBT $1,159,091.00
- KPRX N/A
- Revenue This Year
- ALBT N/A
- KPRX N/A
- Revenue Next Year
- ALBT N/A
- KPRX N/A
- P/E Ratio
- ALBT N/A
- KPRX N/A
- Revenue Growth
- ALBT N/A
- KPRX N/A
- 52 Week Low
- ALBT $1.87
- KPRX $2.25
- 52 Week High
- ALBT $11.66
- KPRX $4.29
- Technical
- Relative Strength Index (RSI)
- ALBT 46.85
- KPRX 59.57
- Support Level
- ALBT $2.17
- KPRX $2.27
- Resistance Level
- ALBT $2.27
- KPRX $2.60
- Average True Range (ATR)
- ALBT 0.20
- KPRX 0.18
- MACD
- ALBT 0.02
- KPRX 0.03
- Stochastic Oscillator
- ALBT 53.25
- KPRX 89.47
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.